NCT07148193 Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)
| NCT ID | NCT07148193 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Technische Universität Dresden |
| Condition | Sarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,600 participants |
| Start Date | 2025-11-28 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,600 participants in total. It began in 2025-11-28 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of sarcoma according to the International Classification of Diseases for Oncology (ICD-O) and World Health Organization (WHO) classification, including soft tissue sarcoma, bone sarcoma, and GIST * At least 5 years since initial sarcoma diagnosis * With or without active disease * Age ≥18 years at the time of study participation Exclusion Criteria: * Diagnosis of Desmoid tumors * Inability to complete a structured questionnaire (e.g., due to insufficient German language skills, cognitive impairment, dementia)
Contact & Investigator
Martin Eichler, Dr.
PRINCIPAL INVESTIGATOR
TU Dresden & NCT/ UCC Dresden
Frequently Asked Questions
Who can join the NCT07148193 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07148193 currently recruiting?
Yes, NCT07148193 is actively recruiting participants. Contact the research team at tanja.strukelj@ukdd.de, for enrollment information.
Where is the NCT07148193 trial being conducted?
This trial is being conducted at Dresden, Germany, Essen, Germany, Heidelberg, Germany, Mannheim, Germany and 1 additional location.
Who is sponsoring the NCT07148193 clinical trial?
NCT07148193 is sponsored by Technische Universität Dresden. The principal investigator is Martin Eichler, Dr. at TU Dresden & NCT/ UCC Dresden. The trial plans to enroll 1,600 participants.